GlassScriptPhysician profile
Kendall Godt
NPI 1487338406
$1,591.20
in general payments reported to CMS, 2019-2025
12 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $128 · 2024: $735 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $430.26 | 2023-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $284.61 | 2024-2025 | Nuplazid |
| Abbvie INC. | $227.91 | 2024-2025 | |
| Axsome Therapeutics, INC. | $181.99 | 2024-2025 | Sunosi, Auvelity |
| Alkermes, INC. | $148.16 | 2024 | Lybalvi, Aristada |
| Lundbeck LLC | $130.22 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $45.20 | 2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $45.12 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $31.33 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.30 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $21.80 | 2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $17.30 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Godt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.